VERU vs. GLYC, RGLS, SCPH, AMLX, SYRE, RENB, LFCR, ACET, FGEN, and IXHL
Should you be buying Veru stock or one of its competitors? The main competitors of Veru include GlycoMimetics (GLYC), Regulus Therapeutics (RGLS), scPharmaceuticals (SCPH), Amylyx Pharmaceuticals (AMLX), Spyre Therapeutics (SYRE), Renovaro (RENB), Lifecore Biomedical (LFCR), Adicet Bio (ACET), FibroGen (FGEN), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical preparations" industry.
GlycoMimetics (NASDAQ:GLYC) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
GlycoMimetics has a net margin of 0.00% compared to GlycoMimetics' net margin of -405.04%. Veru's return on equity of -73.09% beat GlycoMimetics' return on equity.
In the previous week, Veru had 1 more articles in the media than GlycoMimetics. MarketBeat recorded 4 mentions for Veru and 3 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.62 beat Veru's score of 0.43 indicating that Veru is being referred to more favorably in the news media.
GlycoMimetics has higher earnings, but lower revenue than Veru. GlycoMimetics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 8.0% of GlycoMimetics shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
GlycoMimetics currently has a consensus target price of $10.00, indicating a potential upside of 343.46%. Veru has a consensus target price of $3.33, indicating a potential upside of 117.86%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe GlycoMimetics is more favorable than Veru.
GlycoMimetics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Veru has a beta of -0.22, suggesting that its share price is 122% less volatile than the S&P 500.
GlycoMimetics received 48 more outperform votes than Veru when rated by MarketBeat users. However, 69.35% of users gave Veru an outperform vote while only 63.38% of users gave GlycoMimetics an outperform vote.
Summary
GlycoMimetics beats Veru on 11 of the 18 factors compared between the two stocks.
Get Veru News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
